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Abstract : To identify risk factors for restenosis after percutaneous coronary 
intervention with sirolimus （SES）- or paclitaxel （PES）-eluting stents.  The 
clinical outcomes of 894 patients treated with either SES （n＝462） or PES （n
＝432） between January 2005 and January 2010 were evaluated.  Multivariate 
logistic regression analysis showed that long （＞20 mm） （odds ratio ［OR］, 
1.87 ; 95％ condence interval ［CI］, 1.07～3.33 ; P＝0.03） or bent （angle＞
45°） lesions （OR, 2.57 ; 95％ CI, 1.47～4.49 ; P＜0.01） were independent risk 
factors for restenosis with SES, and that hemodialysis （OR, 7.61 ; 95％ CI, 
2.78～20.85 ; P＜0.01） and long （OR, 2.63 ; 95％ CI, 1.18～5.84 ; P＝0.02） 
or bent lesions （OR, 3.47 ; 95％ CI, 1.65～7.27 ; P＜0.01） were independent 
risk factors for target lesion revascularization （TLR） with SES.  In contrast, 
no independent risk factors for restenosis and TLR were found for lesions 
treated with PES.  The rate of TLR was signicantly higher in patients on 
hemodialysis or in those with long lesions in the SES group （hemodialysis, 
30.4％ vs. 11.1％, P＝0.02 ; long lesions, 13.2％ vs. 4.4％, P＜0.01 ; for SES vs. 
PES, respectively）.  Rates of restenosis and TLR were signicantly higher in 
patients with bent lesions in the SES group （restenosis, 30.8％ vs. 15.6％, P＜
0.01 ; TLR, 20.0％ vs. 5.8％, P＜0.01 ; for SES and PES, respectively）.  Most 
clinical studies have described better angiographic results for SES compared 
to PES.  However, PES might result in better clinical outcomes than SES for 
patients on hemodialysis or for those with long or bent lesions.
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Introduction
　The introduction of drug eluting stents （DES） has remarkably improved the restenosis 
rate of percutaneous coronary intervention （PCI）.  However, although DES have revo-
lutionized PCI by signicantly reducing the occurrence of restenosis and revascularization 
compared with bare metal stents during short- and long-term follow-up, restenosis and 
revascularization continue to occur in some patients treated with DES.
　Sirolimus-eluting stents （SES ; CYPHERⓇ ; Cordis Corporation / Johnson and Johnson, 
Miami Lakes, FL） and paclitaxel-eluting stents （PES ; TAXUSTM ; Boston Scientic Corp., 
Natick, MA） are the most studied DES to date.  However, the bare metal stent platform, 
permanent polymer and the antiproliferative drugs signicantly differ between SES and PES. 
Sirolimus is an immunosuppressive drug with antiinammatory properties that arrests the 
cell-cycle at the G1 / S phase transition, whereas paclitaxel is a cytotoxic, antineoplastic drug 
that causes cell-cycle arrest at the G2 / M phase transition1, 2）. Sirolimus-eluting stents are 
based on the rigid and closed-cell, BX velocityⓇ, whereas PES are based on EXPRESSⓇ 
or LIBERTEⓇ that have a exible, open-cell design.  Because these devices differ in terms 
of stent design and polymer construction, the question arises as to whether they differ with 
respect to implementation in PCI.
　Diabetes mellitus3-6）, dialysis7, 8）, long lesions and small vessels9）, as well as chronic and 
total occlusion （CTO）10-15）, have been described as risk factors for restenosis after PCI with 
bare metal stents.  In contrast, risk factors for PCI using DES compared with bare metal 
stents have not been investigated in detail.  A large multi-center study demonstrated similar 
DES efficacy profiles in patients with and without calcified coronary lesions.  However, 
patients with severely calcified lesions were excluded from that trial 16, 17）. Therefore, we 
compared the clinical outcomes of PCI with SES and PES to determine independent risk 
factors for restenosis in such patients.
Methods
Study population
　We analyzed data from 894 consecutive patients with coronary artery disease who were 
treated with SES （January 2005 to May 2007） or PES （May 2007 to January 2010）.  The 
type, length and number of coronary lesions did not inuence the choice of stent.  The 
data were extracted from a retrospective registry of patients at our center where over 400 
procedures per year are performed by ve expert operators.  Baseline clinical, angiographic 
and procedural characteristics as well as in-hospital outcomes were entered into a database 
by physicians.  Clinical outcomes, most importantly major adverse cardiac events （MACE）, 
were recorded at the clinic, or by formal telephone interviews at 1, 8 and 12 months and 
annually thereafter, and later entered into our database.  Patients treated both with SES and 
PES were included in the study.
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Angioplasty procedures
　All angioplasties were performed using a 7- or 8-Fr guiding catheter and the femoral 
approach.  Heparin was administered in boluses to achieve and maintain an activated 
clotting time of more than 250 s.  Aspirin （at least 100 mg for an indenite period） was 
administered immediately after the procedure and continued for as long as possible.  Clopi-
dogrel （loading dose of 300 mg, followed by 75 mg / day for at least one year） or ticlopidine 
（loading dose of 200 mg, followed by 300 mg / day for at least one year） was also started 
immediately after the procedure.  Additional DES were used as necessary when dissection 
arose or lesions were not completely covered.
　Stents were deployed with or without pre-dilation according to standard techniques and 
positioned to completely cover lesions.  Dilation pressure was applied to the stent until the 
lesion was sufciently dilated under transillumination.  Intravascular ultrasound was used dur-
ing all procedures to determine stent diameter pre- and post-dilation and after stenting to 
reconrm the position of the stent.
　The lengths of SES and PES ranged from 13～33 mm and 12～33 mm, respectively, and 
diameters ranged from 2.5～4 mm and 2.25～3.5 mm, respectively.  Aspirin and clopidogrel 
or ticlopidine were started immediately after stent implantation, as described above.
Denitions
　Anginal symptoms were dened according to the classication of the Canadian Cardio-
vascular Society.  Major adverse cardiac events were dened as death, myocardial infarction, 
or target lesion revascularization.  Target restenosis was dened as stenosis of ≥50％ on 
follow-up coronary angiography.  Target vessel revascularization was defined as clinically-
driven percutaneous revascularization or bypass of the target lesion or any segment of the 
epicardial coronary artery including the target lesion.  Target lesion revascularization was 
dened as any repeat revascularization procedure （percutaneous or surgical） at the original 
target lesion site.  The primary endpoint was the occurrence of MACE during follow-up and 
independent predictors, which were compared between the groups.  Calcied lesions were 
dened as identiable radiopaque images on still images obtained before injecting contrast 
agent or an identiable dark area on moving images.  Lesions were dened as being long if 
they were ＞20 mm in length, or being bent if they had a ≥45° bend at the center.  Small 
vessel lesions were dened as having a diameter of ＜2.75 mm.  Procedural success was 
taken as thrombolysis in myocardial infarction ow 3 on nal images and a ≤25％ residual 
rate of stenosis.
Quantitative coronary angiography
　We used the QCA-CMS cardiovascular analysis system （Medis Medical Imaging Systems, 
Raleigh, NC） for coronary angiography.  Lesion length, minimum vascular diameter and 
control vascular diameter were measured from dilation-phase frames taken from the same 
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angle of minimal lesion contraction during pre-treatment, post-treatment and at remote-phase 
follow-up coronary angiography.  Rates of stenosis, acquired inner diameter during the acute 
phase and the loss of inner diameter in the remote phase were calculated.
Statistical analysis
　Quantitative data are presented as means±SD, and categorical data as ratios （％）.  Data 
were statistically analyzed using the chi-square or Fisher’s exact test （two-tailed） for cate-
gorical variables.  Continuous variables were compared using the Student t test and P-values 
≤0.05 were considered signicant.  Univariate and multivariate analyses, including 95％ con-
dence intervals （CI）, were calculated using logistic regression analysis.  Factors with P-values
＜0.05 in the univariate analysis were entered into the multivariate model.  All data were 
statistically analyzed using commercially available software （Stat View for Windows version 
5.0）.
Results
Base characteristics
　The baseline characteristics of 462 and 432 patients who were treated with PCI using SES 
and PES, respectively, over a period of seven years are shown in Table 1.  Age, male sex, 
risk factors （hypertension, dyslipidemia, hyperuricemia, current or previous smoking habit, 
hemodialysis, family history of cardiovascular disease, left ventricular ejection fraction） and 
clinical presentation were similar in both groups.
Angiographic characteristics
　The angiographic characteristics of the patients are shown in Table 2.  The rate of left 
main trunk and left anterior descending artery lesions was signicantly higher in the SES 
（14.5％）, than in the PES group （10.0％ ; respectively, P＝0.04）, while the rate of left 
anterior descending artery was signicantly higher in the PES group （40.5％）, than in the 
SES group （31.2％ ; respectively, P＝0.04）.  The rate of bent lesions was signicantly larger 
in the PES group （35.6％）, than in the SES group （26.0％ ; P＝0.002）, while the rate of 
small vessel lesions was signicantly larger in the SES group （39.8％）, than in the PES 
group （32.2％ ; P＝0.02）.  Pre-PCI, the reference diameter and ％ diameter stenosis were 
signicantly greater in the SES group, than in the PES group （reference diameter, 2.97±1.24 
mmvs. 2.67±0.71 mm, P＝0.03 ; ％ diameter stenosis, 85.1％±13.8％ vs. 80.3％±17.6％, P＝
0.01, for SES vs. PES, respectively）.  The rate of CTO lesions was also signicantly higher 
in the SES group compared to the PES group （20.1％ vs. 12.5％, respectively ; P＝0.03）.
Clinical outcomes
　Data from the one-year clinical follow-up are shown in Table 3.  The rate of restenosis, 
TLR and MACE （death, myocardial infarction, target vessel revascularization） were similar 
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between the two groups.  The rate of TLR tended to be greater in the SES group, but the 
difference was not statistically signicant.
　Results of the univariate and multivariate logistic regression analyses of restenosis and 
TLR are shown in Tables 4 and 5.  Univariate analysis showed that the clinical and 
angiographic risk factors for restenosis in lesions treated with SES were hemodialysis （odds 
ratio ［OR］, 2.96 ; 95％ CI, 1.58～5.55 ; P＜0.01） and calcied （OR, 3.11 ; 95％ CI, 1.84～
5.27 ; P＜0.01）, long （OR, 2.49 ; 95％ CI, 1.48～4.19 ; P＜0.01） and bent lesions （OR, 3.68, 
95％ CI, 2.19～6.16 ; P＜0.01）.  Multivariate logistic regression analysis showed that long 
（OR, 1.87 ; 95％ CI, 1.07～3.33 ; P＝0.03） and bent lesions （OR, 2.57 ; 95％ CI, 1.47～
4.49 ; P＜0.01） were independent risk factors for restenosis after treatment with SES.  On 
the other hand, we found no risk factors for coronary restenosis among lesions treated with 
PES.  Univariate analysis showed that the clinical and angiographic risk factors for TLR 
after treatment with SES were hemodialysis （OR, 7.26 ; 95％ CI, 3.58～14.74 ; P＜0.01） and 
calcied （OR, 3.59 ; 95％ CI, 1.85～6.97 ; P＜0.01）, long （OR, 3.19 ; 95％ CI, 1.55～6.55 ; P
＜0.01） and bent lesions （OR, 5.09 ; 95％ CI, 2.60～9.99 ; P＜0.01）.  Multivariate logistic 
regression analysis showed that hemodialysis （OR, 7.61 ; 95％ CI, 2.78～20.85 ; P＜0.01） and 
long （OR, 2.63 ; 95％ CI, 1.18～5.84 ; P＝0.02） and bent lesions （OR, 3.47 ; 95％ CI, 1.65
～7.27 ; P＜0.01） were independent risk factors for TLR after treatment with SES.  No risk 
Table 1.　Baseline characteristics of the patients.
SES PES p
Patients, n 462 432
Age, years 66.8±10.2 67.6±10.4 0.22
Male, n （％） 368 （79.5） 355 （82.2） 0.38
Risk factors
Hypertension, n （％） 369 （80.0） 322 （74.5） 0.57
Diabetes mellitus, n （％） 257 （55.6） 231 （59.1） 0.31
Dyslipidemia, n （％） 319 （69.0） 253 （65.0） 0.21
Hyperuricemia, n （％） 135 （29.2） 55 （23.9） 0.14
Current or previous smoker, n （％） 303 （65.6） 195 （65.9） 0.93
Hemodialysis, n （％） 56 （12.1） 45 （10.4） 0.42
Family history, n （％） 171 （37.0） 85 （35.7） 0.66
Left ventricular ejection fraction, ％ 52.5±14.2 51.7±12.9 0.55
Clinical presentation
Stable angina, n （％） 198 （42.9） 176 （40.7） 0.52
Unstable angina, n （％） 78 （16.9） 53 （12.3） 0.11
Acute myocardial infarction, n （％） 86 （18.6） 83 （19.2） 0.82
Number of diseased vessels 0.26
1, n （％） 280 （60.6） 243 （56.3）
2, n （％） 134 （29.0） 147 （34.0）
3, n （％） 48 （10.4） 42 （ 9.7）
SES, sirolimus-eluting stent ; PES, paclitaxel-eluting stent.
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factors for TLR were found after treatment with PES.
　Hemodialysis, long and bent lesions were risk factors for TLR in the SES group.  The 
rates of restenosis and TLR in patients on hemodialysis are compared between the two 
groups, SES and PES, in Table 6.  The rates of restenosis in these patients were 32.1％ （n
＝18） and 20.0％ （n＝9） in the SES and PES groups, respectively （P＝0.17）.  The rates 
of TLR in these patients were 30.4％ （n＝17） and 11.1％ （n＝5）, for SES and PES, 
respectively （P＝0.02）.  The rates of restenosis and TLR in patients with long lesions are 
Table 2.　Angiographic characteristics, procedural data and quantitative coronary ndings.
SES PES p
Angiographic characteristics
Target vessels
Left main trunk, n （％） 67 （14.5） 43 （10.0） 0.039
Left anterior descending, n （％） 144 （31.2） 175 （40.5） 0.036
Left circumex, n （％） 111 （24.0） 94 （21.8） 0.42
Right coronary, n （％） 140 （30.3） 147 （34.0） 0.23
Lesion type
Long, n （％） 220 （47.6） 217 （50.2） 0.44
Bent, n （％） 120 （26.0） 154 （35.6） 0.0015
Calcied, n （％） 104 （22.5） 100 （23.1） 0.11
Small vessel, n （％） 184 （39.8） 139 （32.2） 0.017
CTO, n （％） 93 （20.1） 46 （12.5） 0.033
Type B2 / C lesion, n （％） 382（82.7） 343 （79.4） 0.19
Procedural data
Stent diameter, mm 2.98± 0.38 2.90± 0.35 0.75
Stent length, mm 23.2± 5.2 23.1± 6.1 0.94
Balloon diameter, mm 3.14± 0.57 2.98± 0.47 0.57
Balloon pressure, atm 16.0± 4.2 14.2± 3.7 0.73
QCA
Pre-PCI
MLD, mm 0.44± 0.45 0.51± 0.43 0.13
RD, mm 2.97± 1.24 2.67± 0.71 0.032
％DS 85.1± 13.8 80.3± 17.6 0.013
Post-PCI
MLD, mm 2.65± 0.68 3.71± 1.48 0.21
RD, mm 3.11± 0.42 3.05± 0.45 0.35
％DS 14.7± 9.9 20.7± 79.4 0.24
Follow-up
MLD, mm 2.29± 0.76 2.12± 0.73 0.12
RD, mm 3.10± 0.63 4.31± 18.9 0.26
％DS 25.8± 21.0 25.6± 22.6 0.93
Acute gain, mm 2.22± 0.65 2.08± 0.59 0.27
Late loss, mm 0.37± 0.83 0.47± 0.68 0.15
CTO, chronic total occlusion ; MLD, minimal lumen diameter ; QCA, quantitative 
coronary analysis ; RD, reference diameter ; ％DS, ％ diameter stenosis.
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compared between the SES and PES groups in Table 7.  The rates of restenosis in these 
patients were 22.3％ for SES （n＝49） and 17.3％ for PES （n＝43 ; P＝0.18） and those of 
TLR were 13.2％ （n＝29） and 4.4％ （n＝11）, for SES and PES, respectively （P＜0.01）. 
The rates of restenosis and TLR in patients with bent lesions are compared between the 
SES and PES groups in Table 8.  The rates of restenosis in these patients were 30.8％ in 
the SES group （n＝37） and 15.6％ in the PES group （n＝24 ; P＜0.01） and those of TLR 
were 30.8％ （n＝37） and 5.8％ （n＝9）, in the SES and PES groups, respectively （P＜
0.01）.
Table 3.　Clinical outcomes of all patients.
SES （n＝462） PES （n＝432） p
Variable
Restenosis, n （％） 74 （16.0） 76 （17.6） 0.53
Target vessel revascularization, n （％） 49 （10.6） 38 （8.8） 0.36
Target lesion revascularization, n （％） 40 （8.7） 25 （5.8） 0.099
Death, n （％） 3 （0.65） 5 （0.93） 0.42
Myocardial infarction, （％） 3 （0.65） 3 （0.69） 0.93
CABG, n （％） 0 （0.0） 3 （0.69） 0.073
MACE, n （％） 43 （9.3） 34 （7.9） 0.44
MACE, major adverse cardiac events : all cause death, myocardial infarction, target 
lesion revascularization.
Table 4.　Risk factors for restenosis in univariate and multivariate analyses.
 Univariate analysis  Multivariate analysis
Odds ratio 95％ CI p Value Odds ratio 95％ CI p Value
SES
Diabetes mellitus 1.48 0.88 to 2.47 0.14
Hemodialysis 2.96 1.58 to 5.55 ＜0.01 1.753 0.79 to 3.88 0.17
Calcied lesion 3.11 1.84 to 5.27 ＜0.01 1.881 1.00 to 3.66 0.063
CTO 0.97 0.54 to 1.88 0.97
Long lesion 2.49 1.48 to 4.19 ＜0.01 1.894 1.07 to 3.33 0.026
Bent lesion 3.68 2.19 to 6.16 ＜0.01 2.573 1.47 to 4.49 ＜0.01
Small vessel 1.64 0.98 to 2.70 0.53
PES
Diabetes mellitus 0.87 0.53 to 1.42 0.57
Hemodialysis 1.01 0.45 to 2.28 0.97
Calcied lesion 1.81 0.99 to 3.31 0.052
CTO 0.54 0.21 to 1.42 0.21
Long lesion 0.93 0.57 to 1.52 0.77
Bent lesion 0.81 0.47 to 1.35 0.41
Small vessel 1.12 0.66 to 1.89 0.68
CTO, chronic total occlusion.
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Table 5.　Risk factors for target vessel revascularization in univariate and multivariate analysis.
Univariate analysis Multivariate analysis
Odds ratio 95％ CI p Value Odds ratio 95％ CI p Value
SES
Diabetes mellitus 0.17 0.87 - 3.45 0.12
Hemodialysis 7.26 3.58 - 14.74 ＜0.01 7.61 2.78 - 20.86 ＜0.01
Calcied lesion 3.59 1.85 - 6.97 ＜0.01 0.89 0.34 - 2.32 0.81
CTO 0.99 0.44 - 2.23 0.98
Long lesion 3.19 1.55 - 6.55 ＜0.01 2.63 1.18 - 5.84 0.018
Bent lesion 5.09 2.60 - 9.98 ＜0.01 3.47 1.65 - 7.27 ＜0.01
Small vessel 1.01 0.52 - 1.96 0.98
PES
Diabetes mellitus 0.61 0.27 - 1.38 0.24
Hemodialysis 2.29 0.82 - 6.44 0.12
Calcied lesion 1.93 0.71 - 5.21 0.19
CTO 1.15 0.33 - 4.02 0.82
Long lesion 0.64 0.28 - 1.47 0.29
Bent lesion 1.01 0.44 - 2.34 0.98
Small vessel 0.51 0.19 - 1.36 0.19
 CTO, chronic total occlusion.
Table 7.　Comparison of restenosis rates among patients with long lesions.
SES （n＝220） PES （n＝248） p
Restenosis, n （％） 49 （22.3） 43 （17.3） 0.18
Target lesion revascularization, n （％） 29 （13.2） 11 （4.4） ＜0.01
Table 6.　Comparison of restenosis rates among patients on hemodialysis.
SES （n＝56） PES （n＝45） p
Restenosis, n （％） 18 （32.1） 43 （20.0） 0.17
Target lesion revascularization, n （％） 17 （30.4） 5 （11.1） 0.02
Table 8.　Comparison of restenosis rates among patients with bent lesions.
SES （n＝120） PES （n＝154） p
Restenosis, n （％） 37 （30.8） 24 （15.6） ＜0.01
Target lesion revascularization, n （％） 24 （20.0） 9 （5.8） ＜0.01
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Discussion
　Various investigators have cited diabetes, hemodialysis, calcied lesions, CTO, bent lesions, 
long lesions and vessel diameter as risk factors for restenosis after PCI with bare metal 
stents.  However, independent clinical and angiographic risk factors for coronary restenosis 
after SES or PES implantation have never been reported as far as we can ascertain.
　The rates of late loss are lower for SES than for PES.  We also found no signicant 
differences in late loss between SES and PES implantations, although SES was more fre-
quently deployed than PES in small vessels and left main trunk lesions.  In fact, the results 
of many randomized trials have indicated that SES can suppress neo-intimal hyperplasia 
more effectively then PES, and this results in a reduction of in-stent and in-segment late 
loss.  However, this is not always associated with a reduction in binary restenosis, target ves-
sel revascularization and MACE, as shown by the large randomized REALITY trial.18 On 
the other hand, some smaller randomized trials such as ISAR-SMART and SIRTAX have 
identied better angiographic or clinical parameters for SES than for PES 19, 20）.
　Although most clinical comparisons of SES and PES have found better angiographic 
results for SES than PES, the two largest randomized stent trials and several smaller ran-
domized controlled trials and registries have found equivalent clinical outcomes for the two 
types of stents 21-24）.  The present study found no differences between SES and PES in terms 
of clinical MACE, target lesion or vessel revascularization and restenosis, before and after 
adjustment for confounding factors in the setting of a routine practice.  A meta-analysis of 
16 randomized trials of SES versus PES in patients with coronary artery disease indicated 
that SES was more effective than PES in reducing the risk of re-intervention and stent 
thrombosis25）.  Another meta-analysis found a lower frequency of TLR within six months of 
SES deployment and of angiographic restenosis.  However, these analyses included different 
study populations with variable follow-up durations and endpoint denitions, which might 
limit the ability to reach a firm conclusion.  The TAXi-LATE trial compared long-term 
（3-year） clinical outcomes of stenting with SES versus PES.  The ndings of that study 
supported previously published data indicating that both are equivalent in terms of treating 
coronary artery lesions26）.
　The present study uncovered signicant differences in risk factors for restenosis and TLR 
between SES and PES.  The risk factors for restenosis associated with SES were hemodi-
alysis, as well as calcied, long and bent lesions, and the latter two were independent risk 
factors for coronary restenosis.  On the other hand, no risk factors were found for coronary 
restenosis in the PES group.  Risk factors in the SES group for TLR were hemodialysis, 
calcied, long and bent lesions.  Independent risk factors for TLR in the SES group were 
hemodialysis, long and bent lesions, but no risk factors were associated with the PES group. 
Stent design might have played a role in these differences, but whether or not the stent 
platform is directly involved in restenosis has not been reported.  However, some studies 
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have found that the stent platform is associated with stent fracture, which is involved in 
restenosis.  The closed-cell design might cause SES to become more rigid and thus more 
prone to fracture than the open-cell design of PES.  Liao et al 27） investigated the impact 
of the more rigid closed-cell design.  Three-dimensional reconstructions of coronary arteries 
showed that more vessels became straightened with closed-, than with open-cell stents, thus 
changing the shape of the stent ends and generating hinge points that are prone to fracture. 
Bent lesions, overlapping stents and the use of SES have been cited as predictors of stent 
fracture.  Considering that SES and PES almost always overlapped in long lesions in the 
present study, the risk factors for stent fracture and for in-stent restenosis seemed similar.
　Diabetes is a known major risk factor for in-stent restenosis after implantation with bare 
metal stents.  The angiographic rates of restenosis are decreased in patients with diabetes 
after the introduction of DES.  However, Hong et al 28） reported restenosis rates of 20.9％ 
and 14.6％ in patients with and without diabetes, respectively, even after DES implantation. 
The present study found no signicant differences in the rates of restenosis and TLR after 
PCI with SES and PES.
　Mousssa et al 29） reported that the rate of TLR after the deployment of bare metal 
stents is higher in patients who are on hemodialysis than in those who are not.  Stenosis 
in patients on hemodialysis can be caused by chronic vascular inammation, poor dilation 
due to calcication and complications due to dysfunctional organs including the heart.  We 
found no signicant differences in the rates of restenosis and TLR in patients on hemodi-
alysis implanted with PES, but the rate of TLR signicantly differed between such patients 
implanted with SES and PES.  We found no differences in post-procedural minimal lumen 
diameter analyzed by quantitative coronary angiography between patients implanted with 
SES or PES, indicating that technical factors such as poor vessel dilation did not cause 
the high frequency of TLR in patients on hemodialysis implanted with SES.  However, the 
open-cell design of PES is more suitable than the closed-cell design of SES for treating 
complex lesions such as those that are calcied in patients on hemodialysis.  This could 
explain the difference in the rate of TLR between patients on hemodialysis in the SES and 
PES groups.
　Several limitations of the present study need to be addressed.  This study is a registry 
of a single-center experience involving a small patient cohort.  The present ndings require 
conrmation in a larger study.  The unblinded evaluation of coronary angiography might 
have affected operator decisions regarding revascularization.  Although baseline clinical and 
angiographic characteristics did not signicantly differ between the SES and PES groups, the 
selection of the stenting strategy was at the discretion of the operators.  In addition, not all 
patients were followed up by coronary angiography and 12 months might not be a sufcient 
time to discern subsequent outcomes or the relationships identied in the present study.
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Conclusion
　Hemodialysis, and long and bent lesions were high risk factors for revascularization after 
PCI with SES.  Rates of restenosis and TLR in the PES group did not signicantly differ 
among these risk factors.  The rate of TLR was signicantly higher in patients with long or 
bent lesions or patients on hemodialysis in the SES group, than in the PES group.  Most 
clinical studies comparing SES and PES have found better angiographic results for SES 
than PES.  However, PES might result in better clinical outcomes than SES for patients on 
hemodialysis or for those with long or bent lesions.
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